-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/menopause_executive.pdf
March 01, 2015 - 1
Menopausal Symptoms: Comparative
Effectiveness of Therapies
Executive Summary
Background
Menopause is defined as the permanent
cessation of menstruation and ovulation
due to ovarian failure. “Spontaneous”
menopause occurs after 12 months of
amenorrhea as ovarian hormone secretion
diminishes, on average aroun…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/ptsd-dispositIon-comments-2022.pdf
January 01, 2022 - Pharmacologic and Nonpharmacologic Treatments for Posttraumatic Stress Disorder: 2022 Update of the PTSD-Repository Evidence Base
Systematic Review Disposition of Comments Report
Research Review Title: Pharmacologic and Nonpharmacologic Treatments for
Posttraumatic Stress Disorder: 2022 Update of the PTSD-Reposit…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/migraine-prevention_executive.pdf
June 01, 2013 - For
categorical variables we abstracted the number of events
among treatment groups to calculate rates … Means and standard
deviations of continuous variables were abstracted to
calculate mean differences … quantitative analysis set, we abstracted
the number randomized to each treatment group as the
denominator to calculate
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/heart-failure-natriuretic-peptide_research-protocol.pdf
December 20, 2011 - No gold
standard diagnostic criteria exist in HF, so we will calculate sensitivity and specificity … regarding the reference standard,
test performance characteristics (either primary data to allow us to calculate … sample
collection parameters (e.g., tube type, handling, processing, storage);statistical
methods to calculate
-
effectivehealthcare.ahrq.gov/products/psoriasis-chronic/research-protocol
September 27, 2011 - model. 21 In cases where mean change scores from baseline for each group are not reported, we will calculate
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/primary-healthcare-spending-draft-tech-brief-appendix-h.xlsx
January 01, 2011 - Evidence Table H-1
Estimate Number of annual estimates (years) Claims data Non-claims data Other data type Payer type(s) No distinction in definitiona,b Broad general definitiona,c Broad varied definitiona Narrow definitiona,d Method used, if cited Provider taxonomy codes Place of service codes Procedure codes Exclus…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/medical-test-reviews-prognostic.ppt
June 01, 2012 - Step 4: Extracting Statistics To Evaluate Test Performance (9 of 12)
Another way to calculate the net
-
effectivehealthcare.ahrq.gov/sites/default/files/medical-test-reviews-prognostic.ppt
June 01, 2012 - Step 4: Extracting Statistics To Evaluate Test Performance (9 of 12)
Another way to calculate the net
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/choice-of-mean_white-paper.pdf
April 01, 2015 - studies don’t always report ANCOVA estimates, and they rarely report all the
1
necessary data to calculate … We did not calculate the percent
difference between the two combined mean differences since there was
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/vaccine-safety_disposition-comments.pdf
January 01, 2020 - Analytic
approach used to calculate odds ratios using data from
clinical trials and cohort studies … VAERS data not only does not consider the rate of events in
non-vaccinated populations but cannot calculate
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/vaccine-safety_disposition-comments.pdf
January 01, 2020 - Analytic
approach used to calculate odds ratios using data from
clinical trials and cohort studies … VAERS data not only does not consider the rate of events in
non-vaccinated populations but cannot calculate
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/anal-cancer-draft-report.pdf
October 31, 2023 - Treatment of Stages I-III Squamous Cell Anal Cancer: A Systematic Review
i
Draft Comparative Effectiveness Review
Number xx
Treatment of Stages I-III Squamous Cell Anal Cancer:
A Systematic Review
Prepared for:
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
5…
-
effectivehealthcare.ahrq.gov/products/cognitive-decline/research-protocol
March 23, 2016 - outcomes measured with instruments that lack established thresholds to measure improvement, we will calculate … We will calculate risk ratios and absolute risk differences with the corresponding 95 percent confidence
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/registry-of-patient-registries_research-2014_0.pdf
January 01, 2014 - Outcome Measure Framework Design Document
Effective Health Care Program
Number 43
Research Reports
Outcome Measure Framework Design
Document
Richard E. Gliklich, M.D.
Michelle B. Leavy, M.P.H.
Jannette Karl, M.B.A., P.M.P.
Daniel M. Campion, M.B.A.
Daniel Levy, M.S.
May 2014
Research from the Developing Evid…
-
effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/registry-of-patient-registries_research-2014.pdf
January 01, 2014 - Outcome Measure Framework Design Document
Effective Health Care Program
Number 43
Research Reports
Outcome Measure Framework Design
Document
Richard E. Gliklich, M.D.
Michelle B. Leavy, M.P.H.
Jannette Karl, M.B.A., P.M.P.
Daniel M. Campion, M.B.A.
Daniel Levy, M.S.
May 2014
Research from the Developing Evid…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-failure-transition-care_executive.pdf
May 01, 2014 - for NNT indicates that the relative risk (95% CI) was not statistically significant, so we did not calculate … NA for
hazard ratios indicates that we could not calculate an NNT with the data provided by the investigators
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/indirect-comparisons_research-2013.pdf
January 01, 2013 - Suppose that we can calculate the missingness
rate as the summation of the ratio of the number of missing … For example, we cannot directly calculate the
correlation between treatments via correlation between … For instance, we can calculate th
25
e probability of being the best or second best treatment, which … are missing data since they are not fully observe
,
R and MNAR m
) for study
echanisms, we first calculate … We also calculate the
) under Power1 and 2
scenarios because the truth is that
For the rand
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-abnormalities-tests_appendixes.pdf
May 23, 2005 - BIRADS 4-
5, lesions
1.0 cm or
larger
100.0% 14 0 0 0 100.0%
(78.0% to
99.8%)
Could not
calculate … 100.0%
(78.0% to
99.8%)
Could not
calculate
1.93
(1.76 to
2.12)
0.07
(0.00 to
1.91)
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/horizon-scan_research-2015.pdf
January 01, 2015 - Again, we did not attempt to calculate long-term costs and effectiveness. … The cost of these EDs is
difficult to calculate generally for purposes of this report because of the … Based on our estimated patient pool and the manufacturer’s peak
adoption rates, we calculate ocriplasmin
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-future_research.pdf
April 01, 2013 - FRN 35 - Preventive Pharmacological Treatments for Migraine in Adults: Future Research Needs
Future Research Needs Paper
Number 35
Preventive
Pharmacological
Treatments for Migraine
in Adults: Future
Research Needs
Future Research Needs Paper
Number 35
Preventive Pharmacological Treatments for Migraine
in A…